Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)
Urinary Bladder Neoplasm
Eli Lilly and Companyantibody_drug_conjugatePhase 2Active
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 95/ 100
Competitive context
23 Active assets in the Urinary Bladder Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Merck Sharp & Dohme LLC | Phase 2 | BB |
Cis-Diamminedichloroplatinum Ii Merck Sharp & Dohme LLC | Phase 2 | BB |
Pembrolizumab Eli Lilly and Company | Phase 2 | BB |
Nivolumab Ikena Oncology | Phase 2 | B |
5-fluoro-2-deoxycytidine National Cancer Institute (NCI) | Phase 2 | B |
View all 36 →
Same molecule, other indications
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →